8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Jul 21, 2005)

Filed July 21, 2005For Securities:EW

Summary

This 8-K filing from Edwards Lifesciences Corporation, dated July 21, 2005, announces the company's financial results for the second quarter of 2005. The core of the report is the attached press release (Exhibit 99.1), which details the company's performance during the quarter. Investors should pay close attention to this press release for specific financial metrics, operational achievements, and any forward-looking statements made by management. While the 8-K itself is a brief filing, the accompanying press release is the critical document for understanding Edwards Lifesciences' financial condition and results of operations for the second quarter of 2005. This filing serves as an official channel for disseminating these important financial updates to the market.

Key Highlights

  • 1Edwards Lifesciences Corp. filed an 8-K report on July 21, 2005.
  • 2The report pertains to the company's financial results for the second quarter of 2005.
  • 3The primary information is contained within an attached press release (Exhibit 99.1).
  • 4This filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
  • 5The press release details the company's financial results and operations for the period ending Q2 2005.
  • 6Corinne H. Lyle, Corporate Vice President, Chief Financial Officer and Treasurer, signed the report.
  • 7Certain parts of the press release (first two paragraphs and pages 7-13) are deemed filed under the Exchange Act.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce and provide Edwards Lifesciences Corporation's financial results for the second quarter of 2005. It directs investors to a press release containing these details.

The actual financial results for the second quarter of 2005 are detailed in the press release attached as Exhibit 99.1 to this 8-K filing.

According to the filing, the information contained in the first two paragraphs of Exhibit 99.1 and pages 7 through 13, inclusive, of the press release shall be considered to be filed under the Exchange Act.

Corinne H. Lyle is the Corporate Vice President, Chief Financial Officer and Treasurer of Edwards Lifesciences Corporation. Her signature on the 8-K report indicates that the information provided has been reviewed and authorized by the company's senior financial management.